Oxygenta Pharmaceutical Ltd
Un-audited Financial results for the Quarter ended 30.06.2026.
RESULTS
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 27 Jul 2026, 06:05 PM IST · BSE ID: 9113c938-51c3-4ead-9cb8-566043723aa7
View Original BSE Filing (PDF)
💡
In Simple Terms
The company released its financial results for the latest quarter, reporting Rs. 3,699.69 Lakhs in revenue and a net loss.
🤖 AI Summary
- Oxygenta Pharmaceutical reported Revenue from operations of Rs. 3,699.69 Lakhs for Q1 FY27.
- Net Loss for the quarter ended June 30, 2026, stood at Rs. 210.37 Lakhs.
- M/s. PCR & Associates appointed as Cost Auditors for the company for FY 2026-27.
- Annual General Meeting for FY 2025-26 scheduled for August 21, 2026, via Video Conferencing.
- The Board re-constituted the POSH Committee effective July 27, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q1 FY27)
3,699.69 Lakhs
Net Profit / (Loss) for the period (Q1 FY27)
(210.37) Lakhs
Revenue from operations (Q1 FY26)
1513.47 Lakhs
Net Profit / (Loss) for the period (Q1 FY26)
(610.61) Lakhs
Loss before tax (Q1 FY27)
(250.73) Lakhs
Loss before tax (Q1 FY26)
(814.80) Lakhs
Financial assistance availed (Q1 FY27)
399 Lakhs
🏢 How This Affects the Company
The company's core operations generated Rs. 3,699.69 Lakhs in revenue for Q1 FY27. Operations continue solely in pharmaceutical product manufacturing.
Oxygenta Pharmaceutical recorded a net loss of Rs. 210.37 Lakhs for the quarter ended June 30, 2026. The company availed Rs. 399 Lakhs under the Emergency Credit Line Guarantee Scheme.
The appointment of Cost Auditors and reconstitution of the POSH Committee indicate ongoing compliance and governance activities.
The company is actively working to complete the identification of its MSME creditors, requesting self-declaration forms from suppliers to enhance reporting accuracy.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are invited to attend the Annual General Meeting for FY 2025-26 on August 21, 2026, through Video Conferencing/other Audio-Visual Means.
👤
Who Is Affected
All shareholders of Oxygenta Pharmaceutical Limited are affected by the financial results and corporate governance decisions, including the appointment of cost auditors and the upcoming AGM.
🔍
Management Signal
Management is focusing on financial compliance through auditor appointments and ensuring corporate governance with committee reconstitution and scheduled shareholder meetings.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Outcome of the Annual General Meeting on August 21, 2026.
Update on MSME creditor identification in subsequent financial disclosures.
FY 2026-27 annual results for full-year performance.
MEDIUM RISK
Ongoing net losses and the unresolved identification of MSME creditors represent financial and operational risks.
💡 Investor Takeaway
Oxygenta Pharmaceutical reported Revenue from operations of Rs. 3,699.69 Lakhs for Q1 FY27, a significant increase from Rs. 1513.47 Lakhs in Q1 FY26. However, the company recorded a Net Loss of Rs. 210.37 Lakhs for the quarter ended June 30, 2026.
⚖️ Strengths & Concerns
✅ Positives
- Revenue from operations significantly increased to Rs. 3,699.69 Lakhs in Q1 FY27 from Rs. 1513.47 Lakhs in Q1 FY26.
- Loss before tax decreased to Rs. 250.73 Lakhs in Q1 FY27 compared to Rs. 814.80 Lakhs in Q1 FY26.
⚠️ Concerns
- The company reported a Net Loss of Rs. 210.37 Lakhs for the quarter ended June 30, 2026.
- Oxygenta Pharmaceutical is still in the process of identifying all MSME creditors, relying on supplier self-declarations.
📅 Company Track Record
Oxygenta Pharmaceutical's previous Q1 FY27 filing on July 27, 2026, reported revenue from operations at Rs. 3,699.69 Lakhs and a net loss of Rs. 210.37 Lakhs. The Board meeting on July 25, 2026, was specifically to approve these results.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Oxygenta Pharmaceutical's revenue from operations for Q1 FY27?
Oxygenta Pharmaceutical's Revenue from operations for the quarter ended June 30, 2026 (Q1 FY27), was Rs. 3,699.69 Lakhs.
What was the net profit or loss for Oxygenta Pharmaceutical in Q1 FY27?
For the quarter ended June 30, 2026 (Q1 FY27), Oxygenta Pharmaceutical reported a Net Loss of Rs. 210.37 Lakhs.
When is Oxygenta Pharmaceutical's Annual General Meeting for FY 2025-26?
The Annual General Meeting for the financial year 2025-26 is scheduled to be held on Friday, August 21, 2026, at 10:30 a.m. through Video Conferencing/other Audio-Visual Means.
Which firm was appointed as Cost Auditors for Oxygenta Pharmaceutical for FY 2026-27?
M/s. PCR & Associates, Cost Accountants, were appointed as Cost Auditors of Oxygenta Pharmaceutical Limited for the Financial Year 2026-27.
Questions based on this BSE filing only. For information purposes.